Home › All Companies › ASRT › Quarterly Report

Assertio Holdings, Inc. (ASRT) — Quarterly Report

AI-Powered SEC Filing Analysis

← All ASRT filings
Latest Quarterly Report Filed: 2026-05-08

Key Insights

  • The filing shows Q1 2026 results for a specialty pharmaceutical company with multiple product lines including ROLVE DON, INDOCIN, Sympaza, and SPRIX Nasal Spray, indicating an established portfolio but limited financial detail in the provided excerpt.
  • The company has convertible senior notes (6.5%) outstanding as of March 31, 2026, representing a significant debt obligation that could impact equity value through conversion or cash requirements.
  • Recent subsequent events noted in April-May 2026 include product disposal activities and litigation matters (New York Action settled April 30, 2026), suggesting operational restructuring and potential legal liabilities resolution.
  • The presence of multiple litigation matters (Derivative Litigation, Jung Litigation, New York Action) indicates ongoing legal risks that could materially impact financial position and require continued monitoring.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Assertio Holdings, Inc.

Current Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.